Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID, which resumed in 2023, leading to increased acuity and utilization among Elevance's Medicaid members [3][5]. Group 3: Financial Impact and Stock Performance - Elevance had previously stated it was monitoring cost trends related to Medicaid redetermination, but the actual increase in acuity and utilization was not reflected in its financial guidance for 2024 [4][5]. - Following announcements of increased utilization and missed earnings expectations, Elevance's stock price declined significantly: a drop of $32.21 per share (nearly 6%) on July 17, 2024, and a further decline of $52.61 per share (nearly 11%) on October 17, 2024 [6][7].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID-19, which resumed in 2023, leading to increased scrutiny of Medicaid members [3]. Group 3: Financial Implications - Elevance claimed to be monitoring cost trends related to the Medicaid redetermination process, asserting that negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - However, the redetermination process resulted in a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Performance - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing EPS expectations by $1.33 (13.7%) due to elevated medical costs in its Medicaid business, leading to a further decline of $52.61 (nearly 11%) in stock price from $496.96 to $444.35 per share [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Elevance Health, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Elevance Health, Inc. common stock is from April 18, 2024, to October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the Court by July 11, 2025, to represent other class members in the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Elevance Health, Inc. made false or misleading statements regarding the Medicaid redetermination process and its impact on financial guidance [4]. - It is claimed that the acuity and utilization of Medicaid members increased significantly, contrary to the company's assurances to investors [4]. - The misrepresentation of the Medicaid situation led to investor damages when the true details became public [4].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID-19, which resumed in 2023, leading to increased scrutiny of Medicaid members [3]. Group 3: Allegations of Misrepresentation - Elevance allegedly misrepresented its monitoring of cost trends associated with the Medicaid redetermination process and the sufficiency of negotiated rates to address patient risk profiles [4]. - The redetermination process reportedly caused a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Performance and Financial Impact - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, titled Miller v. Elevance Health, Inc., et al., No. 25-cv-0092, with investors having until July 11, 2025, to seek lead plaintiff status [2]. - Claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock [2]. Group 2: Medicaid Management Issues - Elevance provides health insurance plans, including Medicaid benefits, which were subject to a federal pause during COVID-19 that ended in 2023, leading to states resuming eligibility redetermination [3]. - Elevance had previously stated it was monitoring cost trends related to the redetermination process and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. Group 3: Financial Impact and Stock Performance - The redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. - Following an announcement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing EPS expectations by $1.33 (13.7%) due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][2]. Group 1: Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Group 2: Financial Disclosures and Stock Impact - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - On October 17, 2024, Elevance reported Q3 2024 financial results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, and lowered EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [5]. - Following the October announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against Elevance Health, Inc. for allegedly making false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [4]. - Investors who purchased Elevance common stock between April 18, 2024, and October 16, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [3]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Specifics - The lawsuit claims that Elevance Health misrepresented the adequacy of premium rates negotiated with states to address the rising costs associated with Medicaid members, leading to significant investor damages when the true situation was revealed [4].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, titled Miller v. Elevance Health, Inc., et al., No. 25-cv-0092, with investors having until July 11, 2025, to seek lead plaintiff status [2]. - Claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including Medicaid benefits, and was under scrutiny for its management of Medicaid eligibility redeterminations that resumed in 2023 after a federal pause during COVID [3]. - The company claimed to be monitoring cost trends related to the redetermination process and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. Group 3: Financial Impact and Stock Performance - Allegations suggest that the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. - Following a July 17, 2024 announcement regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing EPS expectations by $1.33 (13.7%) due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation - The law firm is looking into claims against Elevance Health, reminding investors of the July 11, 2025 deadline to seek lead plaintiff status in a federal securities class action [2]. - The complaint alleges that Elevance and its executives made false or misleading statements regarding the monitoring of cost trends and the adequacy of premium rates for Medicaid programs [4]. Group 2: Financial Disclosures - On July 17, 2024, Elevance disclosed an expectation of increased Medicaid utilization, leading to a stock price decline of $32.21 per share, or 5.8% [5]. - The company further revealed on October 17, 2024, that it missed consensus earnings per share expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, and lowered its EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [6]. - Following these disclosures, Elevance's stock price fell by another $52.61 per share, or 10.6% [7]. Group 3: Class Action Participation - The lead plaintiff in the class action is the investor with the largest financial interest who directs the litigation on behalf of the class, with options for other members to participate or remain absent [8]. - The firm encourages anyone with information regarding Elevance's conduct to contact them, including whistleblowers and former employees [9].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, titled Miller v. Elevance Health, Inc., et al., No. 25-cv-0092, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Company Operations and Allegations - Elevance Health provides health insurance plans, including contracts with states to administer Medicaid benefits, which were paused during COVID-19 and resumed in 2023 [3]. - The company claimed to be monitoring cost trends related to Medicaid redetermination and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - However, the redetermination process led to a significant increase in the acuity and utilization of Medicaid members, which was not reflected in Elevance's financial guidance for 2024 [5]. Group 3: Stock Performance and Financial Impact - Following the announcement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].